Comparison of autonomic symptoms on Parkinson’s disease and essential tremor with SCOPA-AUT
Objective: To compare the presence of autonomic symptoms on Parkinson's disease (PD) and essential tremor (ET) applying the Scale for Outcomes in Parkinson’s disease for…Phosphodiesterase 10A and cognition in Parkinson’s disease
Objective: We aimed to assess the associations between Phosphodiesterase 10A (PDE10A) expression in the executive striatum and cognitive performance in vivo, using [11C]IMA107 PET and…Primary disruption of the subsystems of the default mode network in drug-naïve Parkinson’s disease with mild cognitive impairments: a resting-state functional connectivity MRI study
Objective: To study changes in subsystems in drug-naïve Parkinson’s disease with mild cognitive impairments using resting-state functional connectivity MRI. Background: Mild cognitive impairment (MCI) is common…Is 18F-FDG-PET/CT a helpful tool to diagnose PSP clinical variants?
Objective: To assess if there are differential metabolic brain patterns among Progressive Supranuclear Palsy(PSP) clinical variants and between them and Parkinson’s disease patients (PD). Background:…Cortical cholinergic dysfunction correlates with microglial activation in the Substantia Innominata in patients with REM sleep behavior disorder
Objective: To explore possible correlations between levels of microglial activation (neuroinflammation) in the Substantia Innominata (SI), the major source of cholinergic input to the cortex,…The efficiency of group cognitive rehabilitation to patients with Parkinson’s disease in comparison to relaxation therapy: pilot data
Objective: The aim of this study was to compare the efficiency of group cognitive rehabilitation to patients with Parkinson´s disease (PD) in comparison to group…Validation of the ‘ecological momentary assessment’ (EMA) method as a tool for daily life monitoring in patients with Parkinson’s disease
Objective: To validate the ‘ecological momentary assessment’ (EMA) method, also known as the ‘experience sampling method’ (ESM), as an instrument to monitor symptoms of PD.…Safinamide improves motor symptoms severity and daily living in Parkinson’s Disease (PD) patients
Objective: To evaluate the clinical effects of safinamide, administered as add-on therapy to levodopa in fluctuating PD patients, on symptoms severity and daily living. Background:…Design, characterization and In vivo evaluation of intranasal delivery of levodopa loaded microspere for Parkinsonism
Objective: Levodopa is the drug of choice in the treatment of Parkinson's disease but it exhibits low oral bioavailability and very low brain uptake. The…Multi-kinase Abelson (c-Abl) and Discoidin Domain Receptors (DDR1/2) inhibitors, Nilotinib, alters CSF soluble TREM2 (sTREM2) in individuals with Parkinson’s Disease
Objective: Our objective was to examine the effects of broad-based tyrosine kinase inhibition in cerebrospinal fluid biomarkers. Background: Nilotinib is a broad-based tyrosine kinase inhibitor…
- « Previous Page
- 1
- …
- 179
- 180
- 181
- 182
- 183
- …
- 388
- Next Page »